Acknowledgement
This paper is supported by the research fund of Dongnam Health University.
References
- Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2018; 2021.
- Park JY, Jang SH. Epidemiology of Lung Cancer in Korea: Recent trends. Tuberculosis and Respiratory Diseases. 2016;79(2):58-69. https://doi.org/10.4046/trd.2016.79.2.58
- Papadopoulos A, Guida F, LeffondrL K, CLnLe S, Cyr D, Schmaus A, et al. Heavy smoking and lung cancer: Are women at higher risk? Result of the ICARE study. Brt J Cancer. 2014;110:1385-91. https://doi.org/10.1038/bjc.2013.821
- McLean AEB, Barnes DJ, Troy LK. Diagnosing lung cancer: The complexities of obtaining a tissue diagnosis in the era of minimally invasive and personalised medicine. J Clin Med. 2018;7(7):163. https://doi.org/10.3390/jcm7070163
- RiihimLki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78-84. https://doi.org/10.1016/j.lungcan.2014.07.020
- Conti M, Bendriem B. The new opportunities for high time resolution clinical TOF PET. Clin Trans Img. 2019;7(2):139-47. https://doi.org/10.1007/s40336-019-00316-5
- Erdi YE. Limits of tumor detectability in nuclear medicine and PET. Mol Img Radionucl Ther. 2012;21(1):23-8. https://doi.org/10.4274/Mirt.138
- Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81(5):1007-15. https://doi.org/10.1016/j.ejrad.2011.01.126
- Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of integrated PET/MRI in head and neck cancer: A preliminary study. Nucl Med Mol Imaging. 2014;48(2):98-105. https://doi.org/10.1007/s13139-013-0252-2
- Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med. 2016;19(3):254-68.
- Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ, et al. PET/MRI: Where might it replace PET/CT? J Magn Reson Imaging. 2017;46(5):1247-62. https://doi.org/10.1002/jmri.25711
- Kwon HW, Becker AK, Goo JM, Cheon GJ. FDG Whole-Body PET/MRI in Oncology: A systematic review. Nucl Med Mol Imaging. 2017;51(1):22-31. https://doi.org/10.1007/s13139-016-0411-3
- Delso G, Ziegler S. PET/MRI system design. Eur J Nucl Med and Mol Imaging. 2009;36:86-92. https://doi.org/10.1007/s00259-008-1008-6
- Jung JH, Choi Y, Im KC. PET/MRI: Technical challenges and recent advances. Nucl Med Mol Imaging. 2016;50(1):3-12. https://doi.org/10.1007/s13139-016-0393-1
- Loeffelbein DJ, Souvatzoglou M, Wankerl V, Martinez-MLller A, Dinges J, Schwaiger M, et al. PET-MRI fusion in head and neck oncology: Current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg. 2012;70(2):473-83. https://doi.org/10.1016/j.joms.2011.02.120
- Nensa F, Beiderwellen K, Heusch P, Wetter A. Clinical applications of PET/MRI: current status and future perspectives. Diagn Interv Radiol. 2014; 20(5):438-47. https://doi.org/10.5152/dir.2014.14008
- Duan XY, Wang W, Li M, Li Y, Guo YM. Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma. Braz J Med Biol Res. 2015;48(3):267-72. https://doi.org/10.1590/1414-431x20144137
- BLsing KA, SchLnberg SO, Brade J, Wasser K. Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT. Nucl Med Biol. 2013;40:206-13. https://doi.org/10.1016/j.nucmedbio.2012.10.014
- Malladi A, Viner M, Jackson T, Mercier G, Subramaniam RM. PET/CT mediastinal and liver FDG uptake: Effects of biological and procedural factors. J Med Imaging Radiat Oncol. 2013;57:169-75. https://doi.org/10.1111/1754-9485.12015
- Kim MY. Relationship between pSUV of 18F-FDG PET/CT and pathological diagnosis in breast cancer. Journal of Radiological Science and Technology. 2013:36(4);305-11.
- Martinez-Moller A, Souvatzoglou M. Tissue classification as a potential approach for attenuation correction in whole-body PET-MRI. J Nucl Med. 2009;50:520-6. https://doi.org/10.2967/jnumed.108.054726
- Catana C, Van der Kouwe A, Benner T, Michel CJ. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med. 2010;51:1431-8. https://doi.org/10.2967/jnumed.109.069112
- Soongsathitanon S, Masa-Ah P, Tuntawiroon M. A new standardized uptake values (SUV) calculation based on pixel intensity values. Math Comput Simul. 2012;6:26-33.
- Franklin WA, Aisner DL, Davies KD. Pathology, biomarkers, and molecular diagnostics. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE (eds) Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:Chap 15.
- Jain S, Pincus MR, Bluth MH, McPherson RA, Bowne WB, Lee P. Diagnosis and management of cancer using serologic and other body fluid markers. In: McPherson RA, Pincus MR (eds) Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. St Louis, MO: Elsevier; 2017:Chap 74.
- Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study. J Nucl Med. 2004;45(9):1519-27.
- Kim JE, Kim JS, Choi NG, Han JB. Evaluation of the liver cancer diagnosis function of PET-MRI based on decision matrix analysis. J Kor Cont Asc. 2017;17(11):50-9. https://doi.org/10.5392/JKCA.2017.17.01.050
- Kang GW, Kim SE, Lee DS, Jeong JK. Koh's nuclear medicine. Kor Med. 2008;(3):8-20.
- Hutton BF, Erlandsson K, Thielemans K. Advances in clinical molecular imaging instrumentation. Clin Transl Imaging. 2018;6:31-5. https://doi.org/10.1007/s40336-018-0264-0
- Cangemi V, Volpino P, Drudi FM, D'Andrea N, Cangemi R, Piat G. Assessment of the accuracy of diagnostic chest CT scanning. Impact on lung cancer management. Int Surg. 1996;81(1):77-82.
- Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Cristina Marzola M, et al. PET/CT imaging in different types of lung cancer: An overview. Eur J Radiol. 2021;81(5):988-1001. https://doi.org/10.1016/j.ejrad.2011.03.020
- Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer. Chest J. 2013;143(5): 211-50.
- Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: Diagnosis and management. Am Fam Physician. 2007;75(1):56-63.
- Rivera MP, Detterbeck F, Mehta AC. Diagnosis of lung cancer* The guidelines. Chest. 2003;123:129-36. https://doi.org/10.1378/chest.123.1_suppl.129S
- Shin GS, Dong GR. The difference of standardized uptake valueon PET-CT according to change of CT parameters. Journal of Radiological Science and Technology. 2007;30(4):373-9.
- Pournazari K, Jahangiri P, Mehdizadeh Seraj S, Khosravi M, Arani L, Torigian D, et al. PET/MRI applications in lung cancer. J Nucl Med. 2018;59(Supplement 1):1157.
- Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, et al. PET/MRI versus PET/CT in oncology: A prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl and Mol Img. 2020;47:51-60. https://doi.org/10.1007/s00259-019-04452-y
- Hartenbach M, Hartenbach S, Bechtloff W, Danz B, Kraft K, Klemenz B, et al. Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: A prospective diagnostic trial. Clin Cancer Res. 2014;20(12):3244-53. https://doi.org/10.1158/1078-0432.CCR-13-2653
- Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138-43. https://doi.org/10.1016/j.lungcan.2011.11.012
- Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83(2):419-24. https://doi.org/10.1016/j.athoracsur.2006.07.079
- Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32(3):435-9. https://doi.org/10.1016/j.ejcts.2007.05.014
- Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg. 2004;78(3):1004-9. https://doi.org/10.1016/j.athoracsur.2004.03.019
- Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: Analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78(1):216-21. https://doi.org/10.1016/j.athoracsur.2004.02.009
- Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat. 2008;62(4):314-20. https://doi.org/10.1198/000313008X370302
- Killeen PR. Beyond statistical inference: A decision theory for science. Psychon Bull Rev. 2006;13(4):549-62. https://doi.org/10.3758/BF03193962
- Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J Nucl Med. 1990:31(12);1927-32.